ObsEva SA Aktie News

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH126004193...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that, concurrent to the decision to wind-down the company's operations, Catarina Edfjäll, Ph.D.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Sw...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist, following the ...

ObsEva Files half Year 202 3 Financial Statements

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland –  Ju ly 13 , 202 3  – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in ...